公开(公告)号：EP0787002A1

公开(公告)日：1997-08-06

申请号：EP95937845.0

申请日：1995-10-24

申请人： SCHERING AKTIENGESELLSCHAFT

发明人： CHWALISZ, Kristof ,  STÖCKEMANN, Klaus ,  SCHMIDT-GOLLWITZER, Karin ,  KLEMANN, Walter

IPC分类号： A61K31 ,  A61P15 ,  C07J9

CPC分类号： A61K31/567 ,  A61K31/00 ,  A61K31/569 ,  A61K31/575 ,  A61K31/58 ,  Y10S514/843

摘要： The present invention concerns the novel use of competitive progesterone antagonists in the preparation of a drug for regulating female fertility as required (pill to be taken as required). This drug can be administered in a single dose at any time during the menstrual cycle, its dosage being less than the ovulation-inhibiting dosage.

公开(公告)号：EP0787002B1

公开(公告)日：2006-12-13

申请号：EP95937845.6

申请日：1995-10-24

申请人： Schering Aktiengesellschaft

发明人： CHWALISZ, Kristof ,  STÖCKEMANN, Klaus ,  SCHMIDT-GOLLWITZER, Karin ,  KLEMANN, Walter

IPC分类号： A61K31/56 ,  A61K31/565 ,  A61K31/575 ,  A61P15/18

CPC分类号： A61K31/567 ,  A61K31/00 ,  A61K31/569 ,  A61K31/575 ,  A61K31/58 ,  Y10S514/843

摘要： The present invention concerns the novel use of competitive progesterone antagonists in the preparation of a drug for regulating female fertility as required (pill to be taken as required). This drug can be administered in a single dose at any time during the menstrual cycle, its dosage being less than the ovulation-inhibiting dosage.

公开(公告)号：EP0835114B1

公开(公告)日：2003-05-07

申请号：EP96922739.6

申请日：1996-06-27

申请人： SCHERING AKTIENGESELLSCHAFT

发明人： SCHMIDT-GOLLWITZER, Karin ,  KLEMANN, Walter

IPC分类号： A61K31/585 ,  A61K31/57 ,  A61K31/565

CPC分类号： A61K31/565 ,  A61K31/57 ,  A61K31/585 ,  Y10S514/843 ,  A61K2300/00

摘要： The invention concerns a two-stage pharmaceutical combined preparation for hormonal contraception containing at least 30 daily doses. The hormonal active substance in the first stage is a combination of an oestrogen preparation and a gestagen preparation in single-stage form in a quantity at least sufficient to inhibit ovulation. In the second stage, the hormonal active substance is an oestrogen preparation only. The first stage comprises not less than 25 and not more than 77 daily discrete or continuous doses and the second stage comprises 5, 6 or 7 daily discrete or continuous doses, the total number of daily units being equal to the total number of days of the desired cycle, i.e. at least thirty and not more than eighty four. This combined preparation can be made available in, for example, monthly packaging and is used for controlling female fertility. It reduces to a minimum the oestrogen content in each individual dose and also has a low overall hormone content for the dosing cycle, while ensuring a high contraceptive reliability, low incidence of follicle development, excellent cycle control and reliable prevention of intercyclic menstrual bleeding and unwanted side effects.

公开(公告)号：EP0835114A1

公开(公告)日：1998-04-15

申请号：EP96922739.0

申请日：1996-06-27

申请人： SCHERING AKTIENGESELLSCHAFT

发明人： SCHMIDT-GOLLWITZER, Karin ,  KLEMANN, Walter

IPC分类号： A61K31 ,  A61P5

CPC分类号： A61K31/565 ,  A61K31/57 ,  A61K31/585 ,  Y10S514/843 ,  A61K2300/00

摘要： The invention concerns a two-stage pharmaceutical combined preparation for hormonal contraception containing at least 30 daily doses. The hormonal active substance in the first stage is a combination of an oestrogen preparation and a gestagen preparation in single-stage form in a quantity at least sufficient to inhibit ovulation. In the second stage, the hormonal active substance is an oestrogen preparation only. The first stage comprises not less than 25 and not more than 77 daily discrete or continuous doses and the second stage comprises 5, 6 or 7 daily discrete or continuous doses, the total number of daily units being equal to the total number of days of the desired cycle, i.e. at least thirty and not more than eighty four. This combined preparation can be made available in, for example, monthly packaging and is used for controlling female fertility. It reduces to a minimum the oestrogen content in each individual dose and also has a low overall hormone content for the dosing cycle, while ensuring a high contraceptive reliability, low incidence of follicle development, excellent cycle control and reliable prevention of intercyclic menstrual bleeding and unwanted side effects.